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ity analyses were performed. RESULTS: Compared to standard
treatment, cinacalcet incurs average additional lifetime costs 
of £21,167 per person and confers an additional 0.34 quality
adjusted life years, resulting in an incremental cost-effectiveness
ratio of £61,890/QALY. This ﬁgure is beyond current UK will-
ingness-to-pay thresholds.. Probabilistic sensitivity analysis
showed that at a threshold of £30,000/QALY there was only a
0.5% probability that cinacalcet could be considered cost-
effective. CONCLUSION: Cinacalcet can reduce levels of serum
biomarkers in the treatment for people with SHPT, however our
model suggest that the long term clinical impact of this is small.
Unless drug costs are considerably reduced, it is unlikely to be
considered cost-effective in the UK setting.
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OBJECTIVES: To evaluate the effect of patent expiry and sub-
sequent market liberalization, with generic substitution and price
decline, on CE ratios of cinacalcet in patients with ESRD on 
dialysis. METHODS: Cinacalcet plus standard of care was 
compared to standard of care alone in the prevention of 
complications associated with uncontrolled mineral metabolism
in patients with ESRD in the UK (National Health Service). Rel-
ative reductions (HRR; 95% CI) in the rates of fractures (0.46;
0.22–0.95), cardiovascular hospitalizations (0.61; 0.43–0.86),
parathyroidectomy (0.07; 0.01–0.55) and all-cause mortality
(0.81; 0.45–1.45), as observed in the pooled analysis of phase 3
trials in 1184 patients were used to build a decision analysis
model. CE ratios of cinacalcet (GBP0.145 per mg, 71.6 mg/day)
were estimated over the lifetime of a 55-year old patient with
ESRD, assuming UK mortality rates and national tariffs for the
diagnosis related group of each complication. Combinations of
price decline and market substitution upon generic market entry
were modeled to start in 2015. CE ratios (2005 GBP per QALY)
were calculated for ten cohorts of 55-year olds, starting in 2006.
A discount rate of 3.5% was used for both costs and clinical ben-
eﬁts; all CE-ratios were discounted to the year 2006. RESULTS:
Baseline (no patent expiry) CE ratio of cinacalcet was
GBP35,600 per QALY gained. CE ratios declined over time as a
function of generic discount and market share. CONCLU-
SIONS: CE ratios decline over time as a function of patient-
expiry and subsequent market liberalization. CE calculations
should account for the likely market dynamics associated with
time-limited intellectual property rights. Market-adjusted CE
ratios may inﬂuence funding decisions contingent upon prede-
termined thresholds.
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OBJECTIVE: The objective was to analyse the cost-effectiveness
of solifenacin succinate ﬂexible dosing for the relief of overac-
tive bladder symptoms (OAB) such as urinary frequency and
urgency with or without incontinence in Norway, Finland,
Sweden and Denmark. METHODS: A decision analytic model
was used to simulate the results for a group of patients with
OAB. The model was built with a 1 year time horizon and com-
pared the cost and effectiveness of solifenacin ﬂexible dosing 
(5 mg and 10 mg) vs. tolterodine 4 mg SR and placebo. The
analysis was based on two large randomised controlled trials.
Resource-use was based on clinical guidelines in the Nordic
countries as well as published literature. Pad use was collected
prospectively in the trials. Unit costs were obtained from ofﬁcial
sources in each of the Nordic countries. Medication, treatment
costs and indirect costs were included in the analysis. Effective-
ness was measured as a reduction in OAB symptoms (urge incon-
tinence episodes, incontinence episodes, urgency episodes and
micturitions) and quality-adjusted life years (QALYs). RESULTS:
For almost all effectiveness parameters, solifenacin ﬂexible
dosing was signiﬁcantly more effective compared to tolterodine
4 mg SR and placebo. Moreover, solifenacin ﬂexible dosing was
less costly compared to tolterodine 4 mg in all Nordic countries
(dominant strategy). Compared to placebo, solifenacin was also
considered a cost-effective treatment strategy, e.g. with a cost per
QALY gained of €27.000 in Sweden. An analysis using solife-
nacin split data for patients taking 5 mg and 10 mg compared to
tolterodine 4 mg SR also showed, that solifenacin was a cost-
effective treatment strategy. CONCLUSION: Solifenacin ﬂexible
dosing is a cost-effective treatment strategy for patients with
OAB in the Nordic countries. A sensitivity analysis using solife-
nacin split data supported this conclusion, which revealed that
the results were robust.
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OBJECTIVES: To demonstrate the need for simulation modeling
to account for the multifactorial aspects and interactions of
factors intrinsic to estimating the cost-effectiveness of treatment
strategies in end-stage renal disease (ESRD). A model of hyper-
phosphataemia treatment was built to predict long-term mor-
bidity, mortality and cost-effectiveness of sevelamer relative to
calcium based binders. METHODS: A discrete event simulation
(DES) was developed based on a published model that predicts
outcomes in dialysis patients through several equations using
coronary artery calciﬁcation scores. The new model utilizes data
and regression equations from two trials comparing outcomes of
sevelamer and calcium treatments, one among incident dialysis
patients as well as the Dialysis Continued Outcomes Revisited
(DCOR), to predict morbidity and mortality directly based on
disease history and other patient characteristics including: age,
gender, time since initiation of dialysis, race, diabetes, heart
failure, peripheral vascular disease, cerebrovascular disease, and
other cardiovascular disease. Outcomes include deaths and hos-
pitalizations due to CVD, fracture, infection, vascular access com-
plications, and other causes. A US perspective is taken and costs
are reported in 2006 US dollars. RESULTS: Simulations were run
over a lifetime comparing treatment with sevelamer to calcium-
based phosphate binders. A set of 10 replications takes less than
one minute to simulate 10,000 patients. Events are output by
type; incremental cost per life year gained and cost per event
avoided are also generated with the corresponding cost-
effectiveness acceptability curves. The model demonstrates that
sevelamer reduces hospitalisation and would be predicted to be
cost-effective in the long-term. CONCLUSIONS: Discrete event
simulation demonstrates the intricacy of factors required to reﬂect
the complicated ESRD pathway, as they provide more ﬂexibility
